How many years can you take Ixazomib?

There is no definite answer to the question of how many years ixazomib can last, because it is affected by many factors, including the patient's specific condition, treatment response, tolerance, and whether to continue receiving other treatments.

According to multiple clinical studies, ixazomib combined with lenalidomide and dexamethasone (IRd regimen) has shown significant efficacy in the treatment of multiple myeloma. For example, a phase III randomized double-blind clinical study included 722 patients with relapsed, refractory, or relapsed and refractory multiple myeloma. The results showed that the median progression-free survival of the ixazomib combination treatment group (PFS) is about 20 months, and the overall response rate is as high as 78.3%. This means that about half of the patients who receive the ixazomib combination will be free of disease progression for 20 months.

However, it is important to note that this is only a median value, indicating that half of the patients will have disease progression before or after this time point. In reality, each patient's specific situation may vary. Some patients may respond very well to treatment with ixazomib and be able to maintain disease control for a long time, while other patients may experience disease progression earlier.

In addition to clinical research data, individual differences among patients are also important factors affecting the maintenance time of ixazomib. Each patient's physical condition, severity of illness, prior treatment history, and drug tolerance are different, and these factors may affect the effectiveness and duration of ixazomib treatment.

For a disease as difficult to cure as multiple myeloma, long-term treatment and monitoring are very important. Even if the patient achieves remission after receiving ixazomib treatment, regular reexamination and monitoring are required to detect disease progression in time and take appropriate treatment measures. In addition, as the disease progresses and treatment time is prolonged, patients may need to adjust their treatment plan, including changing medications or adding other treatments.